• Explore /
  • Poster
  • / A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).

A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).

Abstract Poster

Authors

Jochen Lorch

Jochen H. Lorch

Dana-Farber Cancer Institute, Boston, MA

Jochen H. Lorch , Justine A. Barletta , Matthew Nehs , Ravindra Uppaluri , Erik K. Alexander , Robert I. Haddad , Glenn J. Hanna , Danielle Nina Margalit , Roy B. Tishler , Jonathan Daniel Schoenfeld , Laura A Goguen , Azad Jabiev , Meredith J Sorensen , Sara Ahmadi , Ellen Marqusee , Matthew I Kim , Darren Stanizzi , Ethan Harris , Alec Kacew , David Allen Barbie

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT03246958

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6513)

DOI

10.1200/JCO.2020.38.15_suppl.6513

Abstract #

6513

Poster Bd #

174

Abstract Disclosures

Similar Posters

Poster

2013 ASCO Annual Meeting

A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC).

A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC).

First Author: Jochen H. Lorch

First Author: Vatche Tchekmedyian

First Author: Jiaying Chen

First Author: Shunji Takahashi